Syndax Pharmaceuticals (SNDX) Cash & Equivalents (2015 - 2026)

Syndax Pharmaceuticals' Cash & Equivalents history runs 12 years deep, the most recent figure standing at $130.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 15.0% year-over-year to $130.9 million; the TTM figure through Mar 2026 stood at $130.9 million (down 15.0% YoY), while the FY2025 annual figure was $134.9 million, down 12.43% from the prior year.
• Cash & Equivalents was $130.9 million for Q1 2026 at Syndax Pharmaceuticals, down from $134.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $295.4 million in Q4 2023 to a low of $57.5 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $126.6 million across 5 years, with a median of $116.8 million in 2025.
• Biggest YoY gain for Cash & Equivalents was 297.27% in 2023; the steepest drop was 69.55% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $74.4 million in 2022, then jumped by 297.27% to $295.4 million in 2023, then slumped by 47.84% to $154.1 million in 2024, then decreased by 12.43% to $134.9 million in 2025, then decreased by 2.99% to $130.9 million in 2026.
• The last three Cash & Equivalents figures came in at $130.9 million (Q1 2026), $134.9 million (Q4 2025), and $116.8 million (Q3 2025), per Business Quant data.